Tvardi Therapeutics 3Q 2026: EPS ($0.48) — 10-Q Summary
Tvardi Therapeutics reported a widened net loss of $6.12M for 3Q 2026, up 10.8% YoY, driven by higher R&D costs, particularly for the TTI-101 HCC trial. Diluted EPS was ($0.48). The company had no revenue. TTI-109 showed promising Phase 1 results, with plans to target ulcerative colitis.
How this was made

The 30-second read
Why it matters
The earnings miss and higher cash burn suggest short‑term downside, but the clinical progress may offer long‑term catalysts.
Market read
The filing provides fresh loss and trial‑cost data, likely prompting a sell‑off in TVRD.
What to watch
Potential future partnership or licensing deals for TTI‑101 could offset near‑term losses.
Background
Tvardi Therapeutics filed its Q3 2026 10‑Q, reporting no revenue and increased R&D spend on its lead candidates.
Ticker impact
10-Q shows widened net loss and higher R&D spend on TTI-101 trial.
downward pressure as investors price in higher loss and cash burn
Loss widened 10.8% YoY and EPS fell to -$0.48, with no revenue and increased trial costs.
Market effects
Biotech sector may see broader risk aversion on early‑stage trial cost escalations.
US biotech investors likely to reassess exposure to cash‑burn heavy pipelines.
Limited; impact confined to small‑cap biotech investors.
Counterpoint
If the trial data eventually prove successful, the stock could rebound on long‑term upside.
Key entities
- companyTvardi Therapeutics
US‑listed biotech developing TTI‑101 and TTI‑109.
